TY - JOUR
T1 - Implications of protein corona on physico-chemical and biological properties of magnetic nanoparticles
AU - Yallapu, Murali M.
AU - Chauhan, Neeraj
AU - Othman, Shadi F.
AU - Khalilzad-Sharghi, Vahid
AU - Ebeling, Mara C.
AU - Khan, Sheema
AU - Jaggi, Meena
AU - Chauhan, Subhash C.
N1 - Publisher Copyright:
© 2014 Elsevier Ltd.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Interaction of serum proteins and nanoparticles leads to a nanoparticle-protein complex formation that defines the rational strategy for a clinically relevant formulation for drug delivery, hyperthermia, and magnetic resonance imaging (MRI) applications in cancer nanomedicine. Given this perspective, we have examined the pattern of human serum protein corona formation with our recently engineered magnetic nanoparticles (MNPs). The alteration in particle size, zeta potential, hemotoxicity, cellular uptake/cancer cells targeting potential, and MRI properties of the MNPs after formation of human serum (HS) protein corona were studied. Our results indicated no significant change in particle size of our MNPs upon incubation with 0.5-50wt/v% human serum, while zeta potential of MNPs turned negative due to human serum adsorption. When incubated with an increased serum and particle concentration, apolipoprotein E was adsorbed on the surface of MNPs apart from serum albumin and transferrin. However, there was no significant primary or secondary structural alterations observed in serum proteins through Fourier transform infrared spectroscopy, X-ray diffraction, and circular dichroism. Hemolysis assay suggests almost no hemolysis at the tested concentrations (up to 1mg/mL) for MNPs compared to the sodium dodecyl sulfate (positive control). Additionally, improved internalization and uptake of MNPs by C4-2B and Panc-1 cancer cells were observed upon incubation with human serum (HS). After serum protein adsorption to the surface of MNPs, the close vicinity within T1 (~1.33-1.73s) and T2 (~12.35-13.43ms) relaxation times suggest our MNPs retained inherent MRI potential even after biomolecular protein adsorption. All these superior clinical parameters potentially enable clinical translation and use of this formulation for next generation nanomedicine for drug delivery, cancer-targeting, imaging and theranostic applications.
AB - Interaction of serum proteins and nanoparticles leads to a nanoparticle-protein complex formation that defines the rational strategy for a clinically relevant formulation for drug delivery, hyperthermia, and magnetic resonance imaging (MRI) applications in cancer nanomedicine. Given this perspective, we have examined the pattern of human serum protein corona formation with our recently engineered magnetic nanoparticles (MNPs). The alteration in particle size, zeta potential, hemotoxicity, cellular uptake/cancer cells targeting potential, and MRI properties of the MNPs after formation of human serum (HS) protein corona were studied. Our results indicated no significant change in particle size of our MNPs upon incubation with 0.5-50wt/v% human serum, while zeta potential of MNPs turned negative due to human serum adsorption. When incubated with an increased serum and particle concentration, apolipoprotein E was adsorbed on the surface of MNPs apart from serum albumin and transferrin. However, there was no significant primary or secondary structural alterations observed in serum proteins through Fourier transform infrared spectroscopy, X-ray diffraction, and circular dichroism. Hemolysis assay suggests almost no hemolysis at the tested concentrations (up to 1mg/mL) for MNPs compared to the sodium dodecyl sulfate (positive control). Additionally, improved internalization and uptake of MNPs by C4-2B and Panc-1 cancer cells were observed upon incubation with human serum (HS). After serum protein adsorption to the surface of MNPs, the close vicinity within T1 (~1.33-1.73s) and T2 (~12.35-13.43ms) relaxation times suggest our MNPs retained inherent MRI potential even after biomolecular protein adsorption. All these superior clinical parameters potentially enable clinical translation and use of this formulation for next generation nanomedicine for drug delivery, cancer-targeting, imaging and theranostic applications.
KW - Cancer therapeutics
KW - Drug delivery
KW - Hyperthermia
KW - Magnetic nanoparticles
KW - Magnetic resonance imaging
KW - Protein corona
UR - http://www.scopus.com/inward/record.url?scp=84922792180&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922792180&partnerID=8YFLogxK
U2 - 10.1016/j.biomaterials.2014.12.045
DO - 10.1016/j.biomaterials.2014.12.045
M3 - Article
C2 - 25678111
AN - SCOPUS:84922792180
SN - 0142-9612
VL - 46
SP - 1
EP - 12
JO - Biomaterials
JF - Biomaterials
ER -